CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Carboplatin +1 moredrug
Likely dose
Bevacizumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01295944
NCT01295944Phase 2Completed
CompareCT.gov

Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial

National Cancer Institute (NCI)·interventional·Posted Feb 15, 2011·Updated Aug 5, 2025

In Brief

A Phase 2 clinical trial evaluating Carboplatin and Bevacizumab for Ependymoma and Anaplastic Ependymoma. Completed, enrolled 35 participants across 2 sites.

Detailed Summary

The goal of this clinical research study is to learn if the combination of bevacizumab and carboplatin can help to control recurrent ependymoma. The safety of this drug combination will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpendymoma, Anaplastic Ependymoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 15, 2011
Enrollment StartApr 27, 2011
Primary CompletionSep 23, 2020
Study CompletionMay 14, 2021
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 15.4 years ago

Interventions

Carboplatindrug

Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.

Bevacizumabdrug

Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.